KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $487.4 million.

  • Biomarin Pharmaceutical's Free Cash Flow rose 67.59% to $340.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $832.1 million, marking a year-over-year increase of 160.13%. This contributed to the annual value of $487.4 million for FY2024, which is 679.02% up from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Free Cash Flow stood at $487.4 million for FY2024, which was up 679.02% from $62.6 million recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's Free Cash Flow registered a high of $487.4 million during FY2024, and its lowest value of -$28.9 million during FY2020.
  • In the last 3 years, Biomarin Pharmaceutical's Free Cash Flow had a median value of $62.6 million in 2023 and averaged $201.6 million.
  • In the last 5 years, Biomarin Pharmaceutical's Free Cash Flow soared by 821.86% in 2021 and then slumped by 73.71% in 2022.
  • Yearly analysis of 5 years shows Biomarin Pharmaceutical's Free Cash Flow stood at -$28.9 million in 2020, then surged by 821.86% to $209.0 million in 2021, then plummeted by 73.71% to $54.9 million in 2022, then climbed by 13.88% to $62.6 million in 2023, then soared by 679.02% to $487.4 million in 2024.